The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010.
about
Advances in the treatment of type 2 diabetes: impact of dulaglutidePharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agentsCombination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutideSodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metforminSodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectivesGlycaemic, blood pressure and cholesterol control in 25 629 diabeticsEfficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusInsulin sensitivity and complications in type 1 diabetes: New insightsSodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic ReviewImpact of sodium-glucose cotransporter 2 inhibitors on blood pressurePharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes.Serum uric acid predicts vascular complications in adults with type 1 diabetes: the coronary artery calcification in type 1 diabetes studyGastro-intestinal Quality of Life After Metabolic Surgery for the Treatment of Type 2 Diabetes Mellitus.Affordable Care Act Implementation: Challenges and Opportunities to Impact Patients With Diabetes.National Differences in Remission of Type 2 Diabetes Mellitus After Roux-en-Y Gastric Bypass Surgery-Subgroup Analysis of 2-Year Results of the Diabetes Surgery Study Comparing Taiwanese with Americans with Mild Obesity (BMI 30-35 kg/m2).Impact of glycemic control on healthcare resource utilization and costs of type 2 diabetes: current and future pharmacologic approaches to improving outcomes.Achieving International Society for Pediatric and Adolescent Diabetes and American Diabetes Association clinical guidelines offers cardiorenal protection for youth with type 1 diabetesAssessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials.Current and future management of diabetic retinopathy: a personalized evidence-based approach.The sum of many parts: potential mechanisms for improvement in glucose homeostasis after bariatric surgeryUnderstanding the barriers and improving care in type 2 diabetes: Brazilian perspective in time to do more in diabetesCan diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus.Prevalence of diabetes among Hispanics/Latinos from diverse backgrounds: the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).Health outcomes and retention in care following release from prison for patients of an urban post-incarceration transitions clinicRegression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study.National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011.The use of clinical guidelines highlights ongoing educational gaps in physicians' knowledge and decision making related to diabetes.Patterns of Adherence to Oral Hypoglycemic Agents and Glucose Control among Primary Care Patients with Type 2 Diabetes.Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis.The health system and population health implications of large-scale diabetes screening in India: a microsimulation model of alternative approaches.Dapagliflozin efficacy and safety: a perspective review.Making Insulin Accessible: Does Inhaled Insulin Fill an Unmet Need?Uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension: a retrospective, pooled analysis.Diabetes care and outcomes for American Indians and Alaska natives in commercial integrated delivery systems: a SUrveillance, PREvention, and ManagEment of Diabetes Mellitus (SUPREME-DM) Study.Challenges in preventing heart disease in hispanics: early lessons learned from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).ABC goal achievement predicts microvascular but not macrovascular complications over 6-years in adults with type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes Study.Plasma triglycerides predict incident albuminuria and progression of coronary artery calcification in adults with type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes Study.Clinical inertia in individualising care for diabetes: is there time to do more in type 2 diabetes?Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agentsLong-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes.
P2860
Q26746220-87B59D12-3759-4682-98C4-9794AD040075Q26751138-8A46A562-0980-427B-9D49-468F07CEA916Q26751359-AAC8E6E9-1657-4AD7-AC3E-6534DCA7E36CQ26752815-21AEAB0B-23EA-4692-B339-F14ED83E4A30Q26767263-9C2E38DA-C3CC-4140-8FA0-16D16B6557DBQ26781082-067A390F-23D4-4B2B-A5ED-E97C3F5590B2Q26782225-965301B2-1CAA-432D-81B4-CEA0C9592EA7Q27000205-582CF85F-9A2A-4F46-B1EC-DBE62B5952C9Q28072352-B31B55FB-8244-48CD-B0A7-46F44D50277DQ28080114-90451CBE-FA68-45E9-9A7D-B3614F1E0DE7Q30244827-22E7B87E-A50D-4C97-8375-DD5CBF92A12CQ31165772-0D9E4B20-57A8-42A6-9545-829813C8593CQ33464423-1964CE9E-8E11-40B1-975D-BE129A626FE6Q33587933-A3191B2D-A432-445D-9422-E99ED32CD17CQ33600044-4FE792FE-50E7-4BC7-9CD7-1249F681596CQ33652884-03E0218F-491A-405B-B07B-B8731732C518Q33664505-257E2D00-D47F-4CD9-9256-AA61EEE8B1F7Q33732627-46EC9A1F-E7C4-405E-AF8E-E42CAB9BFEA9Q33738829-74176C7C-404D-4B6A-8956-182FA42ECC0CQ33761529-A42FA5D5-7B27-412B-80ED-299095ECE464Q33805311-B291540C-25EA-4844-8AD5-0D63367CE563Q33949927-EDA092E2-430E-44DC-87C0-128C0156F9F7Q33960266-050E7419-D3C7-454F-8005-F19483E74AE5Q34068472-2229722E-ED88-4A2F-9E89-7FBF57CD5C44Q34073458-B3635B3A-1AB0-441B-86A5-74487106B471Q34122776-48B84A38-71FA-464D-B1C6-B78844896D31Q34174390-70850C20-B23E-4CEF-91C0-143B9C0BDA8CQ34255735-78BFE733-157C-474B-8036-BCD8D71CA8A6Q34456192-D51A99E4-2B03-4348-A7CF-56B5CF22CD8EQ34477117-F7D7123E-40A5-434E-A3A6-112BB9A69555Q34514280-4AB782AD-D718-4F9B-B606-19882823A4F0Q34533154-460A7867-091A-4665-9295-E3F205A8ECBFQ34555388-FA3A53FD-8177-43BA-B7BE-273573A68552Q34583347-8B013786-7B81-459E-8E2F-EFAAE25385D4Q34614307-D87004CE-37F0-4E4C-B848-E0113E94E6D4Q34614907-8F778F79-7F39-4CAA-B521-77675580CBEBQ34718616-89603291-598D-411C-8143-AC7ABBDDA836Q34726295-CD85DEC5-DAA6-46A4-9742-57FDF1E961EEQ34973750-D69B22C6-FE28-4091-8EF3-86E52039D234Q35044151-8E68F735-98C1-4B28-8904-75F162F2D54B
P2860
The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 February 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The prevalence of meeting A1C, ...... ople with diabetes, 1988-2010.
@en
The prevalence of meeting A1C, ...... ople with diabetes, 1988-2010.
@nl
type
label
The prevalence of meeting A1C, ...... ople with diabetes, 1988-2010.
@en
The prevalence of meeting A1C, ...... ople with diabetes, 1988-2010.
@nl
prefLabel
The prevalence of meeting A1C, ...... ople with diabetes, 1988-2010.
@en
The prevalence of meeting A1C, ...... ople with diabetes, 1988-2010.
@nl
P2093
P2860
P356
P1433
P1476
The prevalence of meeting A1C, ...... ople with diabetes, 1988-2010.
@en
P2093
Catherine C Cowie
Judith E Fradkin
Keith F Rust
Sarah Stark Casagrande
Sharon H Saydah
P2860
P304
P356
10.2337/DC12-2258
P407
P577
2013-02-15T00:00:00Z